Resources
View resources about cytomegalovirus and CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) as well as the locations of our upcoming engagements.
Learn More About CYTOGAM With Resources for Your Practice, Institution, and Patients
Easily access printable resources and videos to help train staff on the importance of CMV prevention and educate your patients.
Downloadable and Viewable Materials
CYTOGAM Mechanism of Action Video
This animated video represents components of the mechanism of action of CYTOGAM as “characters” to dynamically illustrate the simultaneous steps that occur.1-3
Antiviral Effect of CMV Immune Globulin After Liver Transplantation5 – Poster Presentation
Dr. Jennifer Chow MD MS, FAST presents key findings from the Tufts Medical Center poster presented at the 2024 ATC meeting .5
Video Series: Cutting-Edge Strategies Against CMV: Breakthroughs in Hyperimmune Therapy
Science and Innovation Theater
Video 1: Kamada Inc., Hyperimmune Globulins, and the US Clinical Program Overview
Presented by Winston Ally, PharmD
Director, US Medical Affairs, Kamada Inc.
Time: 4:09 minutes
Video 2: Anti-CMV Strategies and Immune Response in Lung Transplantation
Presented by Lorenzo Zaffiri, MD, PhD
Associate Medical Director, Lung Transplant Program, Department of Medicine, Cedars-Sinai
Assistant Professor, Department of Medicine
Time: 14:25 minutes
ISHLT Voices Podcast Series: “Unlocking Hyperimmunes – Emerging Clinical Data about Cytogam”
In this episode of ISHLT Voices, you’ll hear a discussion on the utilization of CYTOGAM in solid organ transplantation (SOT) from the following speakers: Martin Zamora, MD, Medical Director of Lung Transplantation, Advent Health, Orlando, FL. Lorenzo Zaffiri, MD, PhD, Medical Director of Lung Transplantation, Emory University, Atlanta, GA and Robert Gottlieb, MD, PhD, FACC, Transplant Cardiologist, Baylor Scott White, Dallas, TX.
Emerging Clinical Data: “Lung transplant recipients with high-risk CMV mismatch managed using a multimodality regimen over a 5-year period”
This poster by UTSW presents findings on a retrospective study of lung-transplant patients receiving CYTOGAM combination prophylaxis with an antiviral.4 A full publication is expected in early 2025.
Emerging Clinical Data: “Antiviral Effect of Cytomegalovirus Immune Globulin after Liver Transplantation in Patients who were not CMV Donor Positive/Recipient Negative”
This post-hoc analysis by Tufts Medical Center purpose was to explore the antiviral effect of CYTOGAM administration post-liver transplant on CMV viral load levels and CMV disease severity in intermediate and low-risk patients.5 A full publication is expected in early 2025.
CYTOGAM Brochure
This 2-page brochure contains an overview of CYTOGAM with an emphasis on how its complementary MOA in conjunction with an antiviral combine to provide CMV prophylaxis.1,2
Upcoming Events
CYTOGAM offers webinars to healthcare providers and their staff periodically. Additionally, Kamada Inc. participates annually in medical conferences in the United States and internationally. Events will be posted below as they become available.
ISHLT 45th Annual Meeting & Scientific Sessions
Join Our Team at the ISHLT Annual Meeting, April 27-30, 2025 in Boston!
At this 45th annual meeting, our team will share recent data and insights into how CYTOGAM may help prevent CMV disease in SOT patients. Join us at booth #400 to learn how CYTOGAM helps protect heart and lung transplant patients.
Let’s connect! Learn more
CMV Stream 2025 – Live Online
Mark your calendar for April 25, 2025 – 3:00 PM EST
Join CMV Stream 2025 for another in-depth discussion on challenging issues and open questions
from the upcoming 4th International Consensus Guidelines on the management of CMV in SOT. Send your questions and insights to the panelists during the broadcast and get their views on your specific topics and queries.
Don’t miss out! Learn more
World Transplant Congress 2025
We’re Exhibiting at WTC, August 2-6, 2025 in San Francisco!
Discover how CYTOGAM may help prevent CMV disease in SOT patients. Visit Kamada’s booth to discuss the clinical benefits and emerging data on CYTOGAM.
Let’s connect! Learn more
References: 1. Grossi PA, Mohacsi P, Szabolcs Z, Potena L. Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016;100:S1-S4. 2. Carbone J. The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100: S11-S18. 3. Deml L, Huber CM, Barabas S, Spindler T, Cozzi E, Grossi P. Stimulatory effect of CMV immunoglobulin on innate immunity and on the immunogenicity of CMV antigens. Transplant Direct. 2021;7:e781. doi:10.1097/TXD.0000000000001236 4. Banga A, Kanade R, Bollineni S, et al. Lung transplant recipients with high-risk CMV mismatch managed using a multimodality regimen over a five-year period. Poster presented at: IDWeek; October 11-15, 2023; Boston, MA. 5. Jennifer K.L. Chow, Laura A. McDermott, David R. Snydman. Antiviral Effect of Cytomegalovirus Immune Globulin after Liver Transplantation in Patients who were not CMV Donor Positive/Recipient Negative. Poster presented at: ATC; June 1-5, 2024; Philadelphia, PA.